^
    over2years
    Clinical and Genomic Features of HER2 exon 20 Insertion Mutations in East Asian NSCLC (IASLC-WCLC 2022)
    In 7 patients who received HER2-directed therapies, limited responses to afatinib (n=5), trastuzumab emtansine (n=3) and tucatinib (n=1) were observed and no responses were seen with immunotherapy monotherapy (n=2). The incidence of HER2-M+ is 3.1% in East Asian non-squamous NSCLC, with only 1/26 HER2ex20 overlapping with activating EGFR mutations. The clinical phenotype and genomic features of HER2ex20 tumours appear distinct from HER2other, the latter demonstrating higher TMB, co-occurring drivers and predominant non-ageing signature. The therapeutic implications of the genomic and clinical features of HER2-M+ warrant further investigation.)
    Clinical • Tumor Mutational Burden • IO biomarker
    |
    EGFR (Epidermal growth factor receptor) • HER-2 (Human epidermal growth factor receptor 2) • TP53 (Tumor protein P53) • TMB (Tumor Mutational Burden)
    |
    TP53 mutation • EGFR mutation • TMB-H • HER-2 mutation • EGFR wild-type • HER-2 exon 20 insertion • TMB-L • HER-2 A775_G776insYVMA • HER-2 L755P • HER-2 Y772_A775dup • HER-2 exon 20 mutation • HER-2 exon 20 YVMA insertion • HER-2 A775 • HER-2 exon 23 mutation
    |
    Gilotrif (afatinib) • Kadcyla (ado-trastuzumab emtansine) • Tukysa (tucatinib)